Surmodics, Inc. (SRDX): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Surmodics, Inc. (SRDX) Bundle
Surmodics, Inc. (SRDX) is transforming the medical device landscape with its innovative solutions aimed at improving patient outcomes. At the heart of its operations lies a comprehensive Business Model Canvas that outlines essential components driving its success. From strategic
- partnerships with healthcare providers
- cutting-edge R&D
- robust customer relationships
Surmodics, Inc. (SRDX) - Business Model: Key Partnerships
Collaboration with Abbott for SurVeil DCB distribution
Surmodics, Inc. has a strategic partnership with Abbott Vascular, Inc. for the distribution of the SurVeil drug-coated balloon (DCB). This partnership is crucial for the commercialization of the SurVeil DCB, which received FDA premarket approval. In the fiscal year 2024, the company recognized $5.1 million in SurVeil DCB license fee revenue, compared to $29.6 million in the prior year, influenced by a milestone payment of $27.0 million from Abbott associated with this approval.
Partnerships with healthcare providers and research institutions
Surmodics collaborates with various healthcare providers and research institutions to enhance its product offerings and clinical validation. This includes partnerships aimed at advancing the clinical applications of its medical devices. The company reported a 34% increase in product sales to $45.6 million within its Medical Device segment, driven by demand for its vascular interventional products, including the Pounce thrombectomy platform and SurVeil DCB.
Engagement with regulatory bodies for compliance
Surmodics actively engages with regulatory bodies, including the U.S. Food and Drug Administration (FDA), to ensure compliance with industry regulations. This engagement is critical for obtaining necessary clearances and approvals for its products, such as the recent FDA 510(k) clearance for the Pounce XL Thrombectomy System.
Alliances with suppliers for raw materials and technologies
Surmodics maintains alliances with various suppliers to secure raw materials and advanced technologies necessary for its product development. These partnerships are essential for maintaining the quality and efficiency of manufacturing processes. As of September 30, 2024, the company reported a total of $40.1 million in cash and investments, which facilitates its ability to engage in strategic sourcing.
| Partnership Type | Partner/Entity | Financial Impact | Year |
|---|---|---|---|
| Distribution | Abbott Vascular, Inc. | $5.1 million in license fee revenue | 2024 |
| Healthcare Providers | Various Institutions | 34% increase in product sales to $45.6 million | 2024 |
| Regulatory Engagement | U.S. FDA | 510(k) clearance for Pounce XL | 2024 |
| Suppliers | Various Suppliers | $40.1 million in cash and investments | 2024 |
Surmodics, Inc. (SRDX) - Business Model: Key Activities
Development of innovative medical devices
Surmodics, Inc. focuses on the development of advanced medical devices, particularly in the vascular intervention space. In fiscal 2024, the Medical Device segment generated revenue of $97.5 million, representing a decrease of 8% compared to $105.8 million in fiscal 2023. The decline was primarily due to a significant drop in SurVeil DCB license fee revenue, which fell from $29.6 million to $5.1 million. However, product sales within this segment increased by 34%, reaching $45.6 million.
Conducting clinical trials and research
Surmodics invests heavily in research and development (R&D). In fiscal 2024, R&D expenses totaled $38.4 million, down from $46.6 million in the previous year. The company has made significant advancements, including receiving FDA 510(k) clearance for its Pounce™ XL Thrombectomy System, which enhances its product offerings in the thrombectomy market. The PROWL registry study demonstrated a procedural flow restoration rate of 96.8% for patients treated with this system.
Manufacturing of high-quality diagnostic components
Surmodics emphasizes high-quality manufacturing processes to ensure the reliability of its diagnostic components. The company reported a product gross margin of 54.6% in the fourth quarter of fiscal 2024, up from 54.2% in the same quarter of fiscal 2023. Total product costs for the year amounted to $33.0 million. The manufacturing strategy includes leveraging production efficiency improvements from key products like the Pounce thrombectomy and Sublime™ radial access device platforms.
Marketing and sales activities for product promotion
Surmodics engages in comprehensive marketing and sales efforts to promote its products. In fiscal 2024, total sales and marketing expenses were approximately $56.8 million. The company reported that its medical device product sales grew by nearly 40% year-over-year, driven by strong demand for its vascular interventional products. The fourth-quarter revenue of $33.2 million represented a 19% increase year-over-year, indicating effective promotional strategies.
| Activity | Fiscal Year 2024 Revenue | Fiscal Year 2023 Revenue | Change (%) |
|---|---|---|---|
| Medical Device Segment | $97.5 million | $105.8 million | -8% |
| In Vitro Diagnostics Segment | $28.6 million | $26.8 million | +7% |
| Total Revenue | $126.1 million | $132.6 million | -5% |
| R&D Expenses | $38.4 million | $46.6 million | -17.6% |
| Marketing and Sales Expenses | $56.8 million | $51.9 million | +9.4% |
Surmodics, Inc. (SRDX) - Business Model: Key Resources
Proprietary coating technologies and patents
Surmodics, Inc. possesses a robust portfolio of proprietary coating technologies that are crucial for its product offerings. These technologies include the Serene™ hydrophilic coating, which is widely utilized in its medical devices. The company holds numerous patents that protect its innovative products, positioning it competitively within the medical device industry. As of 2024, Surmodics has over 45 issued patents and several pending applications, which provide a significant barrier to entry for competitors.
Skilled workforce in engineering and manufacturing
Surmodics employs a highly skilled workforce, with approximately 240 employees dedicated to engineering and manufacturing roles. This team includes engineers specialized in materials science, biomedical engineering, and manufacturing processes. The company invests significantly in employee training and development, ensuring that its workforce remains at the forefront of technological advancements in the medical device sector.
Established supply chain networks
Surmodics has developed strong relationships with suppliers and partners, ensuring a reliable supply chain for its manufacturing processes. The company has strategic partnerships with several key suppliers, which enables it to maintain quality and consistency in its raw materials. As of 2024, Surmodics has established contracts with over 30 suppliers, allowing for flexibility and efficiency in its operations.
Financial resources for R&D and operational needs
Surmodics reported total revenue of $126.1 million for the fiscal year 2024, with a significant portion allocated to research and development. The company spent approximately $38.4 million on R&D in the same fiscal year, representing about 30% of its total revenue. As of September 30, 2024, Surmodics had $40.1 million in cash and investments, along with access to an additional $65 million in debt capital through its revolving credit and term loan facilities.
| Key Resource | Details |
|---|---|
| Proprietary Coating Technologies | Over 45 issued patents; key technologies include Serene™ hydrophilic coating. |
| Skilled Workforce | Approximately 240 employees in engineering and manufacturing; ongoing training programs. |
| Supply Chain Networks | Contracts with over 30 suppliers; strategic partnerships for raw materials. |
| Financial Resources | Total revenue of $126.1 million; R&D expenditure of approximately $38.4 million; $40.1 million in cash and investments. |
Surmodics, Inc. (SRDX) - Business Model: Value Propositions
Advanced medical devices improving patient outcomes
Surmodics, Inc. focuses on developing advanced medical devices that significantly enhance patient outcomes. Their key product lines, including the Pounce™ Thrombectomy System, have demonstrated high efficacy in clinical settings. For instance, early results from the PROWL registry study showed a procedural flow restoration rate of 96.8% in patients treated with the Pounce system.
Customizable performance coatings for various applications
Surmodics offers customizable performance coatings that cater to a variety of medical applications. Their Serene™ hydrophilic coating has seen increased utilization, contributing to a 14% year-over-year growth in performance coating royalties and license fees, which amounted to $37.4 million for fiscal year 2024. This flexibility in product offerings allows clients to tailor solutions that meet specific clinical needs.
Strong focus on innovation and unmet clinical needs
Innovation is at the core of Surmodics' value proposition. The company continually invests in research and development, with $38.4 million allocated in fiscal 2024. This commitment to innovation is reflected in their product advancements and the introduction of new technologies, such as the FDA-cleared Pounce™ XL Thrombectomy System, which expands their market reach.
Reliable products backed by clinical data and research
Surmodics ensures that its products are reliable and effective, supported by robust clinical data. For instance, the company reported a 17% increase in total revenue excluding SurVeil DCB license fee revenue, reaching $121.0 million for fiscal 2024. This growth is indicative of the trust healthcare providers place in Surmodics' products, which are backed by extensive clinical research and validation.
| Value Proposition | Key Metrics | Impact |
|---|---|---|
| Advanced Medical Devices | 96.8% procedural flow restoration rate | Improved patient outcomes |
| Customizable Coatings | $37.4 million in performance coating royalties | Increased client satisfaction and product adaptability |
| Innovation Focus | $38.4 million R&D investment | Growth in product development and market presence |
| Reliability and Clinical Support | $121.0 million total revenue (excl. SurVeil DCB) | Strong market trust and sales growth |
Surmodics, Inc. (SRDX) - Business Model: Customer Relationships
Direct engagement with healthcare professionals
Surmodics actively engages with healthcare professionals through various channels to enhance customer relationships. The company focuses on building trust and credibility by providing access to clinical data and product information. In fiscal year 2024, Surmodics achieved a total revenue of $126.1 million, with significant contributions from direct interactions with healthcare providers that facilitated the adoption of their medical devices, particularly in the vascular intervention sector.
Training and support for product usage and implementation
Surmodics places a strong emphasis on training and support for its products. The company offers comprehensive training programs for healthcare professionals to ensure effective product usage and implementation. In 2024, Surmodics reported a 40% year-over-year growth in product revenue, attributed in part to the enhanced training initiatives that improved user proficiency with their devices.
Feedback mechanisms for continuous improvement
The company utilizes structured feedback mechanisms to gather insights from customers regarding product performance and user experience. This feedback is critical for continuous improvement and innovation in product development. Surmodics has implemented regular surveys and direct communication channels, resulting in actionable insights that contributed to a 17% increase in overall revenue, excluding license fee revenue.
Long-term partnerships with distributors and clients
Surmodics fosters long-term partnerships with distributors and clients, enhancing its market presence and customer loyalty. In 2024, the company entered into agreements that allowed for exclusive distribution of its products, such as the partnership with Abbott for the SurVeil DCB. This partnership significantly impacted revenue, generating $5.1 million in license fees associated with the SurVeil DCB.
| Year | Total Revenue ($ million) | Medical Device Revenue ($ million) | IVD Revenue ($ million) | Growth in Product Revenue (%) | License Fees ($ million) |
|---|---|---|---|---|---|
| 2024 | 126.1 | 97.5 | 28.6 | 40% | 5.1 |
| 2023 | 132.6 | 105.8 | 26.8 | - | 29.6 |
Surmodics, Inc. (SRDX) - Business Model: Channels
Direct sales to hospitals and clinics
Surmodics, Inc. engages in direct sales of its medical devices to hospitals and clinics, focusing on its vascular intervention products, including the Pounce Thrombectomy Platform and SurVeil drug-coated balloon (DCB). In the fourth quarter of fiscal 2024, the company reported product sales of $19.1 million, representing a significant increase from previous quarters, driven by strong demand in the medical device segment.
Distribution partnerships with medical device companies
Surmodics has established crucial distribution partnerships, particularly with Abbott Vascular, which is the exclusive distributor for its SurVeil DCB. This partnership significantly impacts revenue generation, with Medical Device revenue, excluding license fees, increasing by 21% year-over-year to $92.4 million. In fiscal 2024, total Medical Device revenue reached $97.5 million, despite a decline in license fee revenue from $29.6 million to $5.1 million.
Online platforms for information dissemination
Surmodics utilizes online platforms to disseminate information regarding its products and services, enhancing customer engagement. This includes the use of its corporate website for investor relations and product information, which is crucial during the acquisition phase by GTCR, where increased visibility and communication are necessary.
Participation in medical conferences and trade shows
The company actively participates in medical conferences and trade shows to showcase its innovations and network with healthcare professionals. This strategy enhances brand visibility and facilitates direct engagement with potential customers and partners. Participation in such events has been linked to increased awareness and sales of their products, particularly the Pounce system, which was highlighted during the fiscal year.
| Channel Type | Description | Financial Impact (Q4 2024) |
|---|---|---|
| Direct Sales | Sales to hospitals and clinics | $19.1 million in product sales |
| Distribution Partnerships | Collaboration with Abbott Vascular | $97.5 million total Medical Device revenue |
| Online Platforms | Information dissemination via corporate website | N/A |
| Medical Conferences | Participation in industry events | N/A |
Surmodics, Inc. (SRDX) - Business Model: Customer Segments
Hospitals and surgical centers
Surmodics, Inc. serves a significant number of hospitals and surgical centers, focusing on providing innovative medical devices and diagnostic technologies. In fiscal 2024, the Medical Device segment generated approximately $97.5 million in revenue, which represents a decline of 8% from the previous year. This decline can be attributed to reduced revenue from the SurVeil drug-coated balloon (DCB), which dropped to $5.1 million in fiscal 2024 from $29.6 million in fiscal 2023. Despite this, product sales in the Medical Device segment increased by 34% year-over-year, amounting to $45.6 million.
Diagnostic laboratories
Surmodics also targets diagnostic laboratories, providing in vitro diagnostic (IVD) products that facilitated revenue growth in this segment. In fiscal 2024, IVD revenue reached $28.6 million, up 7% from $26.8 million in fiscal 2023. This growth was driven primarily by increased sales of distributed antigen products and microarray slide/surface products, indicating a strong demand for diagnostic solutions in laboratory settings.
Medical professionals in vascular intervention
Medical professionals specializing in vascular intervention constitute another critical customer segment for Surmodics. The company has experienced a surge in demand for its vascular interventional products, particularly the Pounce Thrombectomy Platform, which contributed to a substantial increase in product sales. The overall revenue from the Medical Device segment, excluding DCB license fees, increased by 20% to $23.9 million in the fourth quarter of fiscal 2024. This reflects a broader trend of growth in vascular intervention technologies, aligning with the needs of medical professionals in this field.
Patients requiring specific medical treatments
Lastly, Surmodics targets patients requiring specific medical treatments, particularly those related to vascular conditions. The company's innovative products, such as the Pounce Thrombectomy System, have shown promising results, achieving a procedural flow restoration rate of 96.8% in early studies. This high success rate positions Surmodics' offerings favorably among patients and healthcare providers alike, enhancing the company's value proposition in the medical device market.
| Customer Segment | Revenue (Fiscal 2024) | Growth Rate | Key Products |
|---|---|---|---|
| Hospitals and Surgical Centers | $97.5 million | -8% | SurVeil DCB, Pounce Thrombectomy Platform |
| Diagnostic Laboratories | $28.6 million | +7% | Distributed Antigen Products, Microarray Slide/Surface Products |
| Medical Professionals in Vascular Intervention | $23.9 million | +20% | Pounce Thrombectomy Platform |
| Patients Requiring Specific Medical Treatments | Not Specified | High Success Rate (96.8%) | Pounce Thrombectomy System |
Surmodics, Inc. (SRDX) - Business Model: Cost Structure
R&D expenses for product development
In fiscal 2024, Surmodics incurred $38.36 million in research and development expenses, a decrease from $46.60 million in fiscal 2023. This reflects a strategic focus on enhancing product development while managing costs amidst evolving market conditions.
Manufacturing and production costs
The total product costs for Surmodics in fiscal 2024 amounted to $33.03 million, up from $24.97 million in the previous year. This increase is attributed to heightened production activities and the introduction of new product lines, including the Pounce Thrombectomy Platform, which has seen growing demand.
Marketing and sales expenditures
Marketing and sales expenditures reached $56.84 million in fiscal 2024, compared to $51.88 million in fiscal 2023. This rise includes costs related to increased sales compensation and expenses associated with merger-related activities, which totaled $0.9 million.
Administrative and operational overhead
Administrative expenses, categorized under selling, general and administrative costs, totaled $14.58 million for the fourth quarter of fiscal 2024 and $56.84 million for the full year. Additionally, the company reported $3.50 million in amortization of acquired intangible assets.
| Cost Category | Fiscal Year 2024 ($ millions) | Fiscal Year 2023 ($ millions) | Change ($ millions) |
|---|---|---|---|
| R&D Expenses | 38.36 | 46.60 | -8.24 |
| Product Costs | 33.03 | 24.97 | +8.06 |
| Marketing & Sales Expenses | 56.84 | 51.88 | +4.96 |
| Administrative Expenses | 56.84 | 51.88 | +4.96 |
| Amortization of Intangible Assets | 3.50 | 3.54 | -0.04 |
Overall, Surmodics, Inc. has strategically managed its cost structure by focusing on key areas of R&D and marketing while navigating challenges in production costs and administrative overhead.
Surmodics, Inc. (SRDX) - Business Model: Revenue Streams
Product sales from medical devices
In fiscal year 2024, Surmodics reported medical device revenue of $97.5 million, a decrease of 8% from $105.8 million in the previous year. This revenue included $5.1 million derived from the SurVeil drug-coated balloon license fees, which was significantly lower than the $29.6 million recognized in fiscal 2023 due to a milestone payment associated with FDA approval.
Excluding the SurVeil DCB license fee revenue, medical device product sales increased 34% year-over-year, amounting to $45.6 million compared to $34.1 million in 2023. Key products contributing to this growth included the Pounce thrombectomy device platform and commercial shipments of the SurVeil DCB.
The breakdown of medical device revenue for Q4 2024 shows:
| Revenue Type | Q4 2024 Revenue (in thousands) | Q4 2023 Revenue (in thousands) | Increase/Decrease |
|---|---|---|---|
| Product Sales | $11,844 | $8,533 | $3,311 (39%) |
| Royalties & License Fees | $9,553 | $8,959 | $594 (7%) |
| License Fees – SurVeil DCB | $1,887 | $1,092 | $795 (73%) |
| R&D and Other | $2,470 | $2,460 | $10 (—) |
| Total Medical Device Revenue | $25,754 | $21,044 | $4,710 (22%) |
Royalties and licensing fees from technology partnerships
In fiscal year 2024, Surmodics generated $42.5 million in royalties and licensing fees, down from $62.4 million in the prior year. This decline was largely due to a significant reduction in SurVeil DCB license fees, which accounted for $5.1 million compared to $29.6 million in fiscal 2023. The performance coating royalties and license fee revenue for medical devices was reported at $37.4 million, reflecting a 14% increase from $32.8 million in the previous year.
Revenue from research and development services
Surmodics reported revenue from research and development services amounting to $10 million for fiscal year 2024, slightly up from $9.6 million in fiscal 2023. This revenue stream continues to play a critical role in supporting the company’s innovation initiatives.
Government and private sector grants for innovation projects
Although specific figures for government and private sector grants were not disclosed in the fiscal 2024 financial results, Surmodics has historically received various grants aimed at enhancing its R&D capabilities. These grants are essential for funding projects that align with their strategic focus on innovation in medical devices and diagnostics.
Updated on 16 Nov 2024
Resources:
- Surmodics, Inc. (SRDX) Financial Statements – Access the full quarterly financial statements for Q4 2024 to get an in-depth view of Surmodics, Inc. (SRDX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Surmodics, Inc. (SRDX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.